Sildenafil Prescribing Considerations

Patient Selection

The American College of Cardiology recommends that most erectile dysfunction patients, including those with asymptomatic coronary artery disease with <3 risk factors, controlled hypertension, mild stable angina, successful coronary revascularization, uncomplicated past MI, mild valvular disease, and CHF (NYHA class I), can safely receive sildenafil 1
Patients with severe hepatic impairment generally should not use PDE5 inhibitors, according to the American Association for the Study of Liver Diseases 1

The European Urology Association notes that improvement in erectile function is dose-related for sildenafil (50 mg vs. 25 mg), though less additional benefit occurs when increasing from 50 mg to 100 mg 2
The American Urological Association recommends that before declaring treatment failure, patients should have completed at least 5 separate attempts at maximum dose 1

Men with testosterone deficiency respond less robustly to sildenafil, and combining sildenafil with testosterone therapy may be more effective than sildenafil alone in men with confirmed hypogonadism, according to the Endocrine Society 1
Patients with diabetes and post-prostatectomy have more severe ED at baseline and may respond less robustly, but sildenafil remains effective, as stated by the American Diabetes Association and the American Urological Association 2

The American Heart Association recommends that periodic follow-up should assess efficacy and side effects, verification that cardiovascular health hasn't changed, review of new medications, and changes in health status 1
Serious adverse events occur in <2% of patients, with no significant difference from placebo, according to the National Institutes of Health 3

The American College of Physicians recommends that higher doses of sildenafil are associated with a greater risk for adverse effects, necessitating dose titration to balance efficacy and tolerability, as reported in the Annals of Internal Medicine 4

The American Heart Association guidelines state that both sildenafil and udenafil are absolutely contraindicated with nitrate therapy due to the risk of dangerous, potentially fatal hypotension, according to the Annals of Internal Medicine 4

The American College of Physicians recommends sildenafil as first-line therapy for elderly patients with erectile dysfunction, including those over 70 years of age, due to its high efficacy and safety profile 5
Efficacy is maintained across elderly subgroups, including those with diabetes, with 69% of elderly patients reporting successful sexual intercourse attempts versus 35.5% with placebo, according to the American Geriatrics Society 5

The American Urological Association suggests reducing the dose to 25 mg when co-administered with CYP3A4 inhibitors, such as ritonavir, saquinavir, ketoconazole, erythromycin, or cimetidine, to minimize potential interactions 6

The British Medical Journal recommends periodic follow-up, ideally between 4 weeks and 6 months, to assess efficacy, side effects, cardiovascular status changes, new medications, and overall health status, with dose adjustment or treatment modification as needed 7

The American Diabetes Association notes that elderly patients with diabetes respond well to sildenafil, though baseline ED severity may be greater, and recommends careful consideration of comorbidities and potential interactions 5

Sildenafil is absolutely contraindicated with any form of nitrate medication due to life-threatening hypotension risk 8

Patients with 3 or more cardiac risk factors require cardiovascular assessment before sildenafil treatment 8
Moderate stable angina patients require cardiovascular assessment before sildenafil treatment 8
Recent myocardial infarction (within 2-6 weeks) patients require cardiovascular assessment before sildenafil treatment 8
Heart failure NYHA Class II patients require cardiovascular assessment before sildenafil treatment 8
Unstable or refractory angina patients should defer sexual activity and sildenafil until their cardiac condition is stabilized 8
Heart failure NYHA Class III-IV patients should defer sexual activity and sildenafil until their cardiac condition is stabilized 8
Recent myocardial infarction or stroke (within 2 weeks) patients should defer sexual activity and sildenafil until their cardiac condition is stabilized 8
High-risk arrhythmias patients should defer sexual activity and sildenafil until their cardiac condition is stabilized 8
Hypertrophic obstructive cardiomyopathy patients should defer sexual activity and sildenafil until their cardiac condition is stabilized 8

The American Heart Association recommends that high-risk patients, such as those with unstable or refractory angina, should defer sexual activity and sildenafil until their cardiac condition is stabilized 8